Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 334

1.

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

Kamoun A, Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F; Bladder Cancer Molecular Taxonomy Group.

Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30695-5. doi: 10.1016/j.eururo.2019.09.006. [Epub ahead of print]

2.

The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guérin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Data.

Liem EI, Oddens JR, Vernooij R, Li R, Kamat AM, Dinney CP, Mengual L, Alcaraz A, Izquierdo L, Savic S, Thalmann GN, Bubendorf L, Sylvester RJ, de Reijke TM.

J Urol. 2019 Sep 24:101097JU0000000000000566. doi: 10.1097/JU.0000000000000566. [Epub ahead of print]

PMID:
31549936
3.

Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.

Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM.

Eur Urol Oncol. 2019 May;2(3):286-293. doi: 10.1016/j.euo.2018.08.013. Epub 2018 Sep 10.

PMID:
31200843
4.

Should chemotherapy still be used to treat all muscle invasive bladder cancer in the "era of immunotherapy"?

Duplisea JJ, Dinney CPN.

Expert Rev Anticancer Ther. 2019 Jul;19(7):543-545. doi: 10.1080/14737140.2019.1625773. Epub 2019 Jun 5. No abstract available.

PMID:
31164019
5.

Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation.

Plote D, Choi W, Mokkapati S, Sundi D, Ferguson JE 3rd, Duplisea J, Parker NR, Yla-Herttuala S, Committee SCB, McConkey D, Schluns KS, Dinney CP.

Oncoimmunology. 2019 Feb 20;8(5):e1577125. doi: 10.1080/2162402X.2019.1577125. eCollection 2019.

6.

The role of metastatic burden in cytoreductive/consolidative radical cystectomy.

Li R, Kukreja JEB, Seif MA, Petros FG, Campbell MT, Nguyen JV, González GMN, Kamat AM, Pisters LL, Dinney CP, Navai N.

World J Urol. 2019 Mar 12. doi: 10.1007/s00345-019-02693-y. [Epub ahead of print]

PMID:
30864005
7.

Re: Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer.

Narayan VM, Lim AH, Dinney CPN.

Eur Urol. 2019 Jun;75(6):1034-1035. doi: 10.1016/j.eururo.2019.02.022. Epub 2019 Mar 2. No abstract available.

PMID:
30833138
8.

Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma.

Duplisea JJ, Petros FG, Li R, Fellman B, Guo CC, Czerniak BA, Siefker-Radtke AO, Araujo JC, Dinney CPN, Matin SF.

Urol Oncol. 2019 Jun;37(6):354.e19-354.e26. doi: 10.1016/j.urolonc.2019.01.026. Epub 2019 Feb 16.

PMID:
30777393
9.

The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside.

Duplisea JJ, Mokkapati S, Plote D, Schluns KS, McConkey DJ, Yla-Herttuala S, Parker NR, Dinney CP.

World J Urol. 2019 Oct;37(10):2041-2049. doi: 10.1007/s00345-018-2553-7. Epub 2018 Nov 11. Review.

PMID:
30415317
10.

Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease.

Li R, Tabayoyong WB, Guo CC, González GMN, Navai N, Grossman HB, Dinney CP, Kamat AM.

Eur Urol. 2019 Jan;75(1):8-10. doi: 10.1016/j.eururo.2018.09.028. Epub 2018 Oct 6.

PMID:
30301695
11.

Overall survival in older patients with cancer.

Edwards BJ, Zhang X, Sun M, Song J, Khalil P, Karuturi MS, Pang L, Geng Y, Dinney CP, Valero V, Champlin RE, Tripathy D.

BMJ Support Palliat Care. 2018 Sep 22. pii: bmjspcare-2018-001516. doi: 10.1136/bmjspcare-2018-001516. [Epub ahead of print]

PMID:
30244203
12.

Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma.

Duplisea JJ, Mason RJ, Reichard CA, Li R, Shen Y, Boorjian SA, Dinney CP.

Can Urol Assoc J. 2019 Feb;13(2):24-28. doi: 10.5489/cuaj.5405. Epub 2018 Jul 31.

13.

Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort.

Kukreja JB, Metcalfe MJ, Qiao W, Kamat AM, Dinney CPN, Navai N.

Eur Urol Focus. 2018 Jul 19. pii: S2405-4569(18)30167-6. doi: 10.1016/j.euf.2018.07.001. [Epub ahead of print]

PMID:
30033071
14.

Accuracy of High-Frequency Endoluminal Ultrasonography for Clinical Staging of Upper Tract Urothelial Carcinoma.

Farnum JA, Vikram R, Rao A, Bedi D, Dinney CP, Matin SF.

J Endourol. 2018 Sep 12;32(9):806-811. doi: 10.1089/end.2018.0442. Epub 2018 Aug 21.

PMID:
30014707
15.

Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy.

Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC.

World J Urol. 2019 Jan;37(1):165-172. doi: 10.1007/s00345-018-2361-0. Epub 2018 Jun 7.

PMID:
29882105
16.

Urine cell-based DNA methylation classifier for monitoring bladder cancer.

van der Heijden AG, Mengual L, Ingelmo-Torres M, Lozano JJ, van Rijt-van de Westerlo CCM, Baixauli M, Geavlete B, Moldoveanud C, Ene C, Dinney CP, Czerniak B, Schalken JA, Kiemeney LALM, Ribal MJ, Witjes JA, Alcaraz A.

Clin Epigenetics. 2018 May 30;10:71. doi: 10.1186/s13148-018-0496-x. eCollection 2018.

17.

Salvage topical therapy for upper tract urothelial carcinoma.

Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF.

World J Urol. 2018 Dec;36(12):2027-2034. doi: 10.1007/s00345-018-2349-9. Epub 2018 May 26.

PMID:
29804202
18.

Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases.

Wang G, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC.

Hum Pathol. 2018 Sep;79:57-65. doi: 10.1016/j.humpath.2018.05.005. Epub 2018 May 12.

19.

Serum microRNAs as predictors of risk for non-muscle invasive bladder cancer.

Lian J, Lin SH, Ye Y, Chang DW, Huang M, Dinney CP, Wu X.

Oncotarget. 2018 Feb 12;9(19):14895-14908. doi: 10.18632/oncotarget.24473. eCollection 2018 Mar 13.

20.

Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy.

Mmeje CO, Benson CR, Nogueras-González GM, Jayaratna IS, Gao J, Siefker-Radtke AO, Kamat AM, Dinney CP, Navai N, Shah JB.

BJU Int. 2018 Jul;122(1):89-98. doi: 10.1111/bju.14211. Epub 2018 Apr 23.

21.

Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy.

Kukreja JB, Shi Q, Chang CM, Seif MA, Sterling BM, Chen TY, Creel KM, Kamat AM, Dinney CP, Navai N, Shah JB, Wang XS.

Surg Innov. 2018 Jun;25(3):242-250. doi: 10.1177/1553350618764218. Epub 2018 Mar 20.

22.

Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study.

Tu H, Dinney CP, Ye Y, Grossman HB, Lerner SP, Wu X.

Am J Clin Nutr. 2018 Feb 1;107(2):208-216. doi: 10.1093/ajcn/nqx019.

23.

Cancer risk associated with chronic diseases and disease markers: prospective cohort study.

Tu H, Wen CP, Tsai SP, Chow WH, Wen C, Ye Y, Zhao H, Tsai MK, Huang M, Dinney CP, Tsao CK, Wu X.

BMJ. 2018 Jan 31;360:k134. doi: 10.1136/bmj.k134.

24.

Non-seminomatous germ cell tumor with bone metastasis only at diagnosis: A rare clinical presentation.

Biebighauser KC, Gao J, Rao P, Landon G, Pagliaro L, Dinney CPN, Karam J, Navai N.

Asian J Urol. 2017 Apr;4(2):124-127. doi: 10.1016/j.ajur.2016.08.004. Epub 2016 Aug 26.

25.

Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer.

Westhoff E, Wu X, Kiemeney LA, Lerner SP, Ye Y, Huang M, Dinney CP, Vrieling A, Tu H.

Int J Cancer. 2018 May 1;142(9):1797-1804. doi: 10.1002/ijc.31214. Epub 2017 Dec 26.

26.

Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience.

Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, Karuturi M, Shah JB, Dinney CP, Gagel RF, Valero V, Champlin RE, Tripathy D, Murphy WA Jr.

Support Care Cancer. 2018 May;26(5):1561-1568. doi: 10.1007/s00520-017-3962-7. Epub 2017 Dec 2.

PMID:
29197959
27.

Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin.

Williams SB, Kamat AM, Mmeje C, Ye Y, Huang M, Chang DW, Dinney CP, Wu X.

Oncotarget. 2017 Sep 23;8(51):88782-88791. doi: 10.18632/oncotarget.21222. eCollection 2017 Oct 24.

28.

Effects of thiazolidinedione in patients with active bladder cancer.

Li R, Metcalfe MJ, Ferguson JE 3rd, Mokkapati S, Nogueras González GM, Dinney CP, Navai N, McConkey DJ, Sahai SK, Kamat AM.

BJU Int. 2018 Feb;121(2):244-251. doi: 10.1111/bju.14009. Epub 2017 Sep 23.

29.

Risk factors for falls in older patients with cancer.

Zhang X, Sun M, Liu S, Leung CH, Pang L, Popat UR, Champlin R, Holmes HM, Valero V, Dinney CP, Tripathy D, Edwards BJ.

BMJ Support Palliat Care. 2018 Mar;8(1):34-37. doi: 10.1136/bmjspcare-2017-001388. Epub 2017 Aug 31.

PMID:
28860112
30.

Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index.

Zhang X, Sun M, McKoy JM, Bhulani NNA, Valero V, Barcenas CH, Popat UR, Sri MK, Shah JB, Dinney CP, Hedberg AM, Champlin R, Tripathy D, Holmes HM, Stroehlein JR, Edwards BJ.

J Geriatr Oncol. 2018 Jan;9(1):81-83. doi: 10.1016/j.jgo.2017.07.012. Epub 2017 Aug 24. No abstract available.

PMID:
28844850
31.

Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.

Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN.

J Clin Oncol. 2017 Oct 20;35(30):3410-3416. doi: 10.1200/JCO.2017.72.3064. Epub 2017 Aug 23. Erratum in: J Clin Oncol. 2019 Aug 20;37(24):2187.

32.

Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease.

Li R, Sylvester R, Dinney CP, Kamat AM.

Bladder Cancer. 2017 Jul 27;3(3):147-148. doi: 10.3233/BLC-179020. No abstract available.

33.

High-grade neuroendocrine carcinoma of the urachus-report of 3 cases.

Wang G, Huang H, Kamat AM, Siefker-Radtke A, Dinney CP, Troncoso P, Czerniak B, Guo CC.

Hum Pathol. 2017 Sep;67:126-133. doi: 10.1016/j.humpath.2017.08.003. Epub 2017 Aug 18.

PMID:
28823575
34.

Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.

Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CPN, Shah JB.

Eur Urol Focus. 2018 Sep;4(5):720-724. doi: 10.1016/j.euf.2016.12.005. Epub 2017 Jan 18.

PMID:
28753837
35.

Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.

Metcalfe M, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF.

J Endourol. 2017 Sep;31(9):946-953. doi: 10.1089/end.2016.0871. Epub 2017 Jul 21.

36.

Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration.

Myers AL, Zhang YP, Kawedia JD, Zhou X, Sobocinski SM, Metcalfe MJ, Kramer MA, Dinney CPN, Kamat AM.

Drugs R D. 2017 Jun;17(2):297-304. doi: 10.1007/s40268-017-0183-y.

37.

Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases.

Fox MD, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Zhang L, Dinney CP, Czerniak B, Guo CC.

Am J Clin Pathol. 2017 May 1;147(5):500-506. doi: 10.1093/ajcp/aqx029.

PMID:
28371875
38.

High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis.

Qu K, Gu J, Ye Y, Williams SB, Dinney CP, Wu X, Kamat A.

Oncoimmunology. 2017 Jan 3;6(2):e1265719. doi: 10.1080/2162402X.2016.1265719. eCollection 2017.

39.

Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy.

Roife D, Kang Y, Wang L, Fang B, Swisher SG, Gershenwald JE, Pretzsch S, Dinney CP, Katz MHG, Fleming JB.

Surgery. 2017 May;161(5):1246-1254. doi: 10.1016/j.surg.2016.11.020. Epub 2017 Jan 9.

40.

Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer.

Fernández MI, Williams SB, Willis DL, Slack RS, Dickstein RJ, Parikh S, Chiong E, Siefker-Radtke AO, Guo CC, Czerniak BA, McConkey DJ, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM.

BJU Int. 2017 May;119(5):684-691. doi: 10.1111/bju.13689. Epub 2016 Nov 11.

41.

Pathway analysis of bladder cancer genome-wide association study identifies novel pathways involved in bladder cancer development.

Chen M, Rothman N, Ye Y, Gu J, Scheet PA, Huang M, Chang DW, Dinney CP, Silverman DT, Figueroa JD, Chanock SJ, Wu X.

Genes Cancer. 2016 Jul;7(7-8):229-239.

42.

Intrinsic subtypes and bladder cancer metastasis.

McConkey DJ, Choi W, Ochoa A, Dinney CPN.

Asian J Urol. 2016 Oct;3(4):260-267. doi: 10.1016/j.ajur.2016.09.009. Epub 2016 Sep 23. Review.

43.

Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional study.

Oshiro H, Czerniak BA, Sakamaki K, Tsuta K, Bondaruk J, Keyhani A, Dinney CP, Nagai T, Kamat AM.

Medicine (Baltimore). 2016 Aug;95(31):e4500. doi: 10.1097/MD.0000000000004500.

44.
45.

Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ.

Bladder Cancer. 2016 Apr 27;2(2):165-202.

46.

Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.

Chedgy EC, Douglas J, Wright JL, Seiler R, van Rhijn BW, Boormans J, Todenhöfer T, Dinney CP, Collins CC, Van der Heijden MS, Black PC.

Urol Oncol. 2016 Oct;34(10):469-76. doi: 10.1016/j.urolonc.2016.05.012. Epub 2016 Jun 15. Review.

PMID:
27317490
47.

Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer.

Williams SB, Huo J, Chamie K, Hu JC, Giordano SH, Hoffman KE, Dinney CPN, Kamat AM, Shih YT.

Eur Urol Focus. 2017 Apr;3(2-3):258-264. doi: 10.1016/j.euf.2016.04.008. Epub 2016 May 13.

PMID:
28753760
48.

Oncologic Equivalence between Laparoscopic/Robotic and Open Radical Cystectomy.

Navai N, Dinney CP.

J Urol. 2016 Jun;195(6):1646-7. doi: 10.1016/j.juro.2016.03.067. Epub 2016 Mar 16. No abstract available.

PMID:
26994308
49.

Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.

Mmeje CO, Guo CC, Shah JB, Navai N, Grossman HB, Dinney CP, Kamat AM.

Eur Urol. 2016 Nov;70(5):778-785. doi: 10.1016/j.eururo.2016.02.031. Epub 2016 Feb 24.

50.

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer.

Jayaratna IS, Navai N, Dinney CP.

Transl Androl Urol. 2015 Jun;4(3):273-82. doi: 10.3978/j.issn.2223-4683.2015.06.07. Review.

Supplemental Content

Loading ...
Support Center